Cargando…

Prescreening whole exome sequencing results from patients with retinal degeneration for variants in genes associated with retinal degeneration

BACKGROUND: Accurate clinical diagnosis and prognosis of retinal degeneration can be aided by the identification of the disease-causing genetic variant. It can confirm the clinical diagnosis as well as inform the clinician of the risk for potential involvement of other organs such as kidneys. It als...

Descripción completa

Detalles Bibliográficos
Autores principales: Bryant, Laura, Lozynska, Olga, Maguire, Albert M, Aleman, Tomas S, Bennett, Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749571/
https://www.ncbi.nlm.nih.gov/pubmed/29343940
http://dx.doi.org/10.2147/OPTH.S147684
_version_ 1783289607093223424
author Bryant, Laura
Lozynska, Olga
Maguire, Albert M
Aleman, Tomas S
Bennett, Jean
author_facet Bryant, Laura
Lozynska, Olga
Maguire, Albert M
Aleman, Tomas S
Bennett, Jean
author_sort Bryant, Laura
collection PubMed
description BACKGROUND: Accurate clinical diagnosis and prognosis of retinal degeneration can be aided by the identification of the disease-causing genetic variant. It can confirm the clinical diagnosis as well as inform the clinician of the risk for potential involvement of other organs such as kidneys. It also aids in genetic counseling for affected individuals who want to have a child. Finally, knowledge of disease-causing variants informs laboratory investigators involved in translational research. With the advent of next-generation sequencing, identifying pathogenic mutations is becoming easier, especially the identification of novel pathogenic variants. METHODS: We used whole exome sequencing on a cohort of 69 patients with various forms of retinal degeneration and in whom screens for previously identified disease-causing variants had been inconclusive. All potential pathogenic variants were verified by Sanger sequencing and, when possible, segregation analysis of immediate relatives. Potential variants were identified by using a semi-masked approach in which rare variants in candidate genes were identified without knowledge of the clinical diagnosis (beyond “retinal degeneration”) or inheritance pattern. After the initial list of genes was prioritized, genetic diagnosis and inheritance pattern were taken into account. RESULTS: We identified the likely pathogenic variants in 64% of the subjects. Seven percent had a single heterozygous mutation identified that would cause recessive disease and 13% had no obviously pathogenic variants and no family members available to perform segregation analysis. Eleven subjects are good candidates for novel gene discovery. Two de novo mutations were identified that resulted in dominant retinal degeneration. CONCLUSION: Whole exome sequencing allows for thorough genetic analysis of candidate genes as well as novel gene discovery. It allows for an unbiased analysis of genetic variants to reduce the chance that the pathogenic mutation will be missed due to incomplete or inaccurate family history or analysis at the early stage of a syndromic form of retinal degeneration.
format Online
Article
Text
id pubmed-5749571
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-57495712018-01-17 Prescreening whole exome sequencing results from patients with retinal degeneration for variants in genes associated with retinal degeneration Bryant, Laura Lozynska, Olga Maguire, Albert M Aleman, Tomas S Bennett, Jean Clin Ophthalmol Original Research BACKGROUND: Accurate clinical diagnosis and prognosis of retinal degeneration can be aided by the identification of the disease-causing genetic variant. It can confirm the clinical diagnosis as well as inform the clinician of the risk for potential involvement of other organs such as kidneys. It also aids in genetic counseling for affected individuals who want to have a child. Finally, knowledge of disease-causing variants informs laboratory investigators involved in translational research. With the advent of next-generation sequencing, identifying pathogenic mutations is becoming easier, especially the identification of novel pathogenic variants. METHODS: We used whole exome sequencing on a cohort of 69 patients with various forms of retinal degeneration and in whom screens for previously identified disease-causing variants had been inconclusive. All potential pathogenic variants were verified by Sanger sequencing and, when possible, segregation analysis of immediate relatives. Potential variants were identified by using a semi-masked approach in which rare variants in candidate genes were identified without knowledge of the clinical diagnosis (beyond “retinal degeneration”) or inheritance pattern. After the initial list of genes was prioritized, genetic diagnosis and inheritance pattern were taken into account. RESULTS: We identified the likely pathogenic variants in 64% of the subjects. Seven percent had a single heterozygous mutation identified that would cause recessive disease and 13% had no obviously pathogenic variants and no family members available to perform segregation analysis. Eleven subjects are good candidates for novel gene discovery. Two de novo mutations were identified that resulted in dominant retinal degeneration. CONCLUSION: Whole exome sequencing allows for thorough genetic analysis of candidate genes as well as novel gene discovery. It allows for an unbiased analysis of genetic variants to reduce the chance that the pathogenic mutation will be missed due to incomplete or inaccurate family history or analysis at the early stage of a syndromic form of retinal degeneration. Dove Medical Press 2017-12-29 /pmc/articles/PMC5749571/ /pubmed/29343940 http://dx.doi.org/10.2147/OPTH.S147684 Text en © 2018 Bryant et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Bryant, Laura
Lozynska, Olga
Maguire, Albert M
Aleman, Tomas S
Bennett, Jean
Prescreening whole exome sequencing results from patients with retinal degeneration for variants in genes associated with retinal degeneration
title Prescreening whole exome sequencing results from patients with retinal degeneration for variants in genes associated with retinal degeneration
title_full Prescreening whole exome sequencing results from patients with retinal degeneration for variants in genes associated with retinal degeneration
title_fullStr Prescreening whole exome sequencing results from patients with retinal degeneration for variants in genes associated with retinal degeneration
title_full_unstemmed Prescreening whole exome sequencing results from patients with retinal degeneration for variants in genes associated with retinal degeneration
title_short Prescreening whole exome sequencing results from patients with retinal degeneration for variants in genes associated with retinal degeneration
title_sort prescreening whole exome sequencing results from patients with retinal degeneration for variants in genes associated with retinal degeneration
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749571/
https://www.ncbi.nlm.nih.gov/pubmed/29343940
http://dx.doi.org/10.2147/OPTH.S147684
work_keys_str_mv AT bryantlaura prescreeningwholeexomesequencingresultsfrompatientswithretinaldegenerationforvariantsingenesassociatedwithretinaldegeneration
AT lozynskaolga prescreeningwholeexomesequencingresultsfrompatientswithretinaldegenerationforvariantsingenesassociatedwithretinaldegeneration
AT maguirealbertm prescreeningwholeexomesequencingresultsfrompatientswithretinaldegenerationforvariantsingenesassociatedwithretinaldegeneration
AT alemantomass prescreeningwholeexomesequencingresultsfrompatientswithretinaldegenerationforvariantsingenesassociatedwithretinaldegeneration
AT bennettjean prescreeningwholeexomesequencingresultsfrompatientswithretinaldegenerationforvariantsingenesassociatedwithretinaldegeneration